Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells

SEC Filings

SEC Filings

Form Description Filing date View
3

Initial filing by director officer or owner of more than ten percent.

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
10-K

Annual report which provides a comprehensive overview of the company for the past year

EX-101.INS - XBRL INSTANCE DOCUMENT View HTML
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML

Copyright Morningstar



Copyright 2018 - Stemline Therapeutics, Inc. All rights reserved